Transgenomic's Q2 Revenues Dip 7 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market Thursday that its second-quarter revenues declined 7 percent and its net loss jumped more than 50 percent year over year.

The Omaha, Nebraska-based companion diagnostics and genetic analysis tools firm had total sales of $5.1 million for the three-month period ended June 30, down from $5.5 million for Q2 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.